Biotech startup aims to advance groundbreaking T-cell therapies
Affini-T Therapeutics completes $175 million financing co-led by Vida Ventures and Leaps by Bayer
28-Mar-2022 -
Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, announced the completion of an oversubscribed $175 million financing co-led by Vida Ventures and Leaps by Bayer, the impact investment unit of Bayer. Additional investors ...
cancer
cancer therapy
cell therapies
+2